Robotic surgery has experienced a dramatic increase in utilization across general surgery over the last two decades, including in surgical oncology. Although urologists and gynecologists were the first to show that this technology could be utilized in cancer surgery, the robot is now a powerful tool in the treatment of gastrointestinal, hepato-pancreatico-biliary, colorectal, endocrine, and soft tissue malignancies. While long-term outcomes are still pending, short-term outcomes have showed promise for this technologic advancement of cancer surgery.
View Article and Find Full Text PDFSince the introduction of robotic pancreas surgery in the early 2000s, there has been significant increase in the adoption of the robot to perform complex pancreatic resections. However, utilization of the robot for pancreatic cancer has lagged behind due to concern for inferior oncologic outcomes. Furthermore, research in this field has previously been limited to small, single institution observational studies.
View Article and Find Full Text PDFObjective: This study sought to investigate the impact of minimally invasive surgery (MIS) on recurrence and overall survival between patients with pancreatic head versus body/tail cancers.
Methods: The risk factors associated with recurrence and long-term outcomes were analyzed according to tumor location and operative modality.
Results: A total of 288 and 87 patients underwent surgical resection for pancreatic head cancer and body/tail cancer, respectively.
Introduction: Laparoscopic hepatectomies for centrally located tumors are classified as advanced and complex surgical procedures. Because of some limitations in robotic liver surgery, robotic central bisectionectomy has rarely been performed. We introduce useful tips for robotic central bisectionectomy in this multimedia article.
View Article and Find Full Text PDF